DEA Places Strict Sanctions on Hydrocodone to Crack Down on Opioid Abuse

Katie Eder, Senior Editor
Published Online: Friday, August 22, 2014
Follow Pharmacy_Times:
Drugs that contain hydrocodone will be moved to a more restrictive category of the Controlled Substances Act.

In an effort to curb rampant opioid abuse and addiction, the Drug Enforcement Administration (DEA) is imposing stricter regulatory sanctions on hydrocodone, the most frequently prescribed painkiller in the United States.
 
“Almost 7 million Americans abuse controlled-substance prescription medications, including opioid painkillers, resulting in more deaths from prescription drug overdoses than auto accidents,” said DEA Administrator Michele Leonhart in a statement released Thursday. “Today’s action recognizes that these products are some of the most addictive and potentially dangerous prescription medications available.”
 
Under the new rule, which will be implemented on October 6, 2014, drugs that contain hydrocodone, such as Vicodin, will be moved from Schedule III of the Controlled Substances Act to the more restrictive Schedule II, where substances with the highest potential for harm and abuse are classified.
 
Nathaniel Katz, MD, MS, assistant professor of anesthesia at Tufts University School of Medicine, told The New York Times that the move is “substantial” and “a sign of a shift toward more cautious opioid prescribing.”
 
“This will be an inconvenience to some, but policy is a machete, not a scalpel, and you have to figure out where to use it,” Dr. Katz continued. “I think people will be more helped than harmed.”
 
According to the Associated Press, the new rule comes more than a decade after the DEA first recommended moving hydrocodone to Schedule II. Although the FDA originally opposed the move, arguing it would burden health care providers and patients, the agency reversed its position last year, recognizing the record growth in opioid-related overdoses.
 
In the AP story, the advocacy group Physicians for Responsible Opioid Prescribing (PROP) praised the DEA’s action, but criticized the FDA’s inaction throughout the last decade.
 
“Had FDA responded in a timely and appropriate manner to DEA’s urgent request, thousands of overdose deaths and tens of thousands of cases of opioid addiction might have been prevented,” PROP said.


Related Articles
Responding to a request from state officials to provide greater access to naloxone, CVS Health, Walgreens, and other chain pharmacies will stock and dispense the opioid overdose antidote in stores across Maryland, as well as train their pharmacists on administering the lifesaving medication.
New research posits that cocaine use quadruples the risk of sudden cardiovascular death among individuals aged 19 to 49 years.
With Pennsylvania pharmacies now authorized to fill third-party naloxone prescriptions and California pharmacies set to dispense naloxone without any prescription at all, more and more pharmacists are providing a critical public pathway to the opioid overdose antidote.
Mylan Inc. announced the U.S. launch of its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg, one of the first available generic versions of Pfizer's Celebrex® Capsules, which is indicated for the relief of the signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and for the management of acute pain in adults.
Latest Issues
$auto_registration$